Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2025-02-14 Capital/Financing Update
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders
Capital/Financing Update Classification · 99% confidence The document is a press release from GENFIT dated February 14, 2025, announcing the amendment of the final terms for a dual proposal related to its 2025 OCEANEs (convertible bonds). The proposal involves either repurchasing the bonds or paying a consent fee, contingent on the approval of an Amendment of Terms related to a Royalty Financing deal. This announcement concerns corporate financing activities, specifically related to debt instruments (bonds) and capital structure adjustments contingent on a financing agreement. This aligns best with the 'Capital/Financing Update' category, as it details changes to outstanding debt terms and associated fees/repurchases linked to a major financing event (Royalty Financing). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital structure modification.
2025-02-14 English
GENFIT annonce la modification des termes définitifs de la double proposition aux porteurs d’OCEANEs 2025
Capital/Financing Update Classification · 99% confidence The document is a press release from GENFIT dated February 14, 2025, announcing the modification of definitive terms for a dual proposal concerning its outstanding OCEANEs 2025 bonds. This proposal involves either a repurchase of the bonds or a financial consideration payment, contingent on shareholder approval for a Royalty Financing agreement. The text explicitly mentions convening a general meeting of OCEANEs 2025 holders and that a 'Sollicitation Memorandum' will be published shortly. This content relates to corporate actions, financing, and soliciting shareholder votes regarding debt restructuring/financing, which falls under Capital/Financing Update (CAP) or potentially Proxy Solicitation (PSI) if the focus was purely on the proxy materials. However, since the core announcement is about the terms of a financing deal (Royalty Financing) and the associated bond repurchase/consideration, 'Capital/Financing Update' (CAP) is the most appropriate primary classification, as it details the structure and terms of a significant financial transaction affecting the capital structure. It is not an ER (Earnings Release), 10-K (Annual Report), or IR (Interim Report). It is an announcement about a proposed transaction, not the final voting results (DVA) or the proxy materials themselves (PSI), although it precedes the distribution of the Sollicitation Memorandum.
2025-02-14 French
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders
Capital/Financing Update Classification · 95% confidence The document is a press release from GENFIT detailing the final terms of a repurchase proposal and consent fee for its 2025 OCEANEs (convertible bonds). This relates directly to the company's capital structure and financing activities, specifically the management of existing debt instruments in conjunction with a new royalty financing agreement. As it describes specific financial terms for bondholders and capital restructuring, it falls under the 'Capital/Financing Update' category.
2025-02-10 English
GENFIT annonce les termes définitifs de sa double proposition aux porteurs d’OCEANEs 2025
Capital/Financing Update Classification · 95% confidence The document is a press release from GENFIT announcing the definitive terms of a tender offer and financial proposal for its 2025 convertible bonds (OCEANEs 2025) in connection with a previously announced royalty financing agreement. It details the specific financial terms (32.00 EUR buyback or 0.60 EUR financial consideration) and the conditions for shareholder approval. As this is a corporate announcement regarding capital structure and financing activities, it falls under the 'Capital/Financing Update' category.
2025-02-10 French
GENFIT présente le design de ses prochains essais cliniques et rappelle les grandes étapes de développement et données cliniques attendues en 2025
Regulatory Filings Classification · 95% confidence The document is a press release from GENFIT titled 'COMMUNIQUÉ DE PRESSE'. It details the company's clinical trial designs, development milestones, and expected clinical data for 2025. It provides strategic updates on their ACLF (Acute on-Chronic Liver Failure) portfolio and pipeline. This type of document, which provides updates on business strategy, clinical trial progress, and forward-looking statements without being a formal quarterly or annual financial report, is best classified as a Regulatory Filing (RNS) or a general corporate announcement.
2025-02-06 French
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
Regulatory Filings Classification · 95% confidence The document is a press release from GENFIT outlining clinical trial initiations, development milestones, and data readouts for 2025. It provides strategic updates on the company's R&D pipeline and clinical progress. As it is a corporate announcement regarding business operations and clinical development rather than a formal financial report, a regulatory filing, or a specific investor presentation deck, it falls under the category of general regulatory announcements/press releases.
2025-02-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.